Goserelin
- Generic Name
- Goserelin
- Brand Names
- Zoladex
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N18O14
- CAS Number
- 65807-02-5
- Unique Ingredient Identifier
- 0F65R8P09N
- Background
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
- Indication
Goserelin is indicated for:
- Associated Conditions
- Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate
- Associated Therapies
- Palliative Treatment
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 41
- Registration Number
- NCT00028769
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸CCOP - Central Illinois, Decatur, Illinois, United States
S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2022-12-30
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 983
- Registration Number
- NCT00004124
- Locations
- 🇺🇸
Cancer Care Center at Advocate Lutheran Hospital, Park Ridge, Illinois, United States
🇺🇸Alta Bates Comprehensive Cancer Center, Berkeley, California, United States
🇺🇸Bismarck Cancer Center, Bismarck, North Dakota, United States
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 1386
- Registration Number
- NCT00003653
- Locations
- 🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇨🇦BCCA - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada
🇨🇦Clinical Research Unit at Vancouver Coastal, Vancouver, British Columbia, Canada
Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence
- Conditions
- MelanomaNeoplasm Metastasis
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 141
- Registration Number
- NCT00001705
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2000-02-21
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 159
- Registration Number
- NCT00004635
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Wayne State University Hutzel Hospital, Detroit, Michigan, United States
🇺🇸University of Washington, Seattle, Washington, United States
A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas
- Conditions
- Ewing's SarcomaRhabdomyosarcoma
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00001564
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.